
The work of David Allison and his colleagues may be familiar to Retraction Watch readers. Allison was the researcher — then at the University of Alabama, Birmingham, now at Indiana University — who led an effort to correct the nutrition literature a few years ago. He and his colleagues are back, this time with what might be called the “Regression to the Mean Project,” an attempt to fix a problem that seems to vex many clinical trials. You may have noticed some items in Weekend Reads about letters to the editor that mention the issue. Here, Allison explains.
Retraction Watch (RW): First, what is “regression to the mean,” and what does it mean for clinical studies? Continue reading The “regression to the mean project:” What researchers should know about a mistake many make
The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”
Tokyo Women’s Medical University has stripped a researcher of her PhD, following the retraction of a paper — for data duplication — that was based on her thesis.
Journals have retracted all but 19 of the 313 tainted papers linked to three of the most notorious fraudsters in science, with only stragglers left in the literature. But editors and publishers have been less diligent when it comes to delivering optimal retraction notices for the affected articles.
The authors of a 2018 paper on how noisy distractions disrupt memory are retracting the article after finding a flaw in their study.
Researchers have retracted a 2015 Nature paper about the molecular underpinnings of immune function after discovering they could not replicate key parts of the results.
Earlier this year, the president of the Karolinska Institute,